JO
NBIX icon

John Overdeck’s Neurocrine Biosciences NBIX Stock Holding History

John Overdeck’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-4,200
Closed -$213K – 3377
2016
Q3 		$213K Buy
+4,200
New +$209K ﹤0.01% 2922

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

John Overdeck's NBIX Position: Q2 2026 in Review

John Overdeck reduced its Neurocrine Biosciences (NBIX) stake by 32% in Q2 2026, selling an estimated $146M and leaving 2,076,260 shares worth $350M. The position accounts for 0.25% of the portfolio, ranked #73.

John Overdeck first reported a position in NBIX in Q2 2013 and has held it in 38 quarters since. The position peaked at $403M in Q1 2026. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • John Overdeck held 2,076,260 shares of Neurocrine Biosciences worth $350M as of Q2 2026.
  • John Overdeck sold 984,310 Neurocrine Biosciences shares in Q2 2026, an estimated $146M.
  • Neurocrine Biosciences made up 0.25% of John Overdeck's portfolio in Q2 2026, its #73 holding.
  • John Overdeck first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 38 quarters since.
  • John Overdeck's Neurocrine Biosciences position peaked at $403M in Q1 2026.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.